Definium Therapeutics(DFTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DFTX Definium Therapeutics

Trading 05-14 11:17:42 EDT

21.73

-0.28

-1.27%

High22.23	Low21.62	Vol223.71K
Open22.10	D1 Closing22.01	Amplitude2.76%
Mkt Cap2.37B	Tradable Cap2.24B	Total Shares109.00M
T/O4.89M	T/O Rate0.22%	Tradable Shares103.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DFTX","market":"US","secType":"STK","nameCN":"Definium Therapeutics","latestPrice":21.73,"timestamp":1778771857737,"preClose":22.01,"halted":0,"volume":223709,"delay":0,"changeRate":-0.012721490231712908,"floatShares":103000000,"shares":109000000,"eps":-2.49367,"marketStatus":"Trading","change":-0.28,"latestTime":"05-14 11:17:42 EDT","open":22.1,"high":22.2267,"low":21.6184,"amount":4888109.657536,"amplitude":0.027637,"askPrice":21.75,"askSize":221,"bidPrice":21.73,"bidSize":113,"shortable":3,"etf":0,"ttmEps":-2.49367,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1778788800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":22.01,"preHourTrading":{"tag":"盘前","latestPrice":22.3,"preClose":22.01,"latestTime":"09:27 EDT","volume":2185,"amount":48196.015505,"timestamp":1778765259795,"change":0.29,"changeRate":0.013176,"amplitude":0.013176},"postHourTrading":{"tag":"盘后","latestPrice":22.3877,"preClose":22.01,"latestTime":"19:59 EDT","volume":44765,"amount":985454.808,"timestamp":1778716744726,"change":0.3777,"changeRate":0.01716,"amplitude":0.028719},"volumeRatio":0.504987,"impliedVol":1.2056,"impliedVolPercentile":0.9634},"requestUrl":"/m/hq/s/DFTX/wiki","defaultTab":"wiki","newsList":[{"id":"1138713954","title":"Stock Track | Definium Therapeutics Soars 5.15% Intraday After Analyst Reiterates Buy Rating with $70 Price Target on Pipeline Confidence","url":"https://stock-news.laohu8.com/highlight/detail?id=1138713954","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138713954?lang=en_us&edition=fundamental","pubTime":"2026-05-14 01:45","pubTimestamp":1778694302,"startTime":"0","endTime":"0","summary":"Definium Therapeutics (DFTX) stock soared 5.15% during intraday trading on Wednesday, marking a significant upward movement.The surge follows a positive analyst note from H.C. Wainwright, where...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635090783","title":"Definium Therapeutics: Buy Rating Reiterated with Unchanged $70 Price Target on Robust Late-Stage DT120 Pipeline and De-Risked Phase 3 Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2635090783","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635090783?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:35","pubTimestamp":1778668536,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on DFTX stock, giving a Buy rating today. Patrick Trucchio has given h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/definium-therapeutics-buy-rating-reiterated-with-unchanged-70-price-target-on-robust-late-stage-dt120-pipeline-and-de-risked-phase-3-programs-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/definium-therapeutics-buy-rating-reiterated-with-unchanged-70-price-target-on-robust-late-stage-dt120-pipeline-and-de-risked-phase-3-programs-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","SSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634111902","title":"Definium Therapeutics says first patient dosed in Ascend study","url":"https://stock-news.laohu8.com/highlight/detail?id=2634111902","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634111902?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:39","pubTimestamp":1778589593,"startTime":"0","endTime":"0","summary":"Definium Therapeutics (DFTX) announced that the first patient has been dosed in Ascend, its second Phase 3 study evaluating DT120 ODT for the treat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-says-first-patient-dosed-in-ascend-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-says-first-patient-dosed-in-ascend-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634145218","title":"BRIEF-Definium Therapeutics Announces First Patient Dosed In Ascend","url":"https://stock-news.laohu8.com/highlight/detail?id=2634145218","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634145218?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:00","pubTimestamp":1778583658,"startTime":"0","endTime":"0","summary":"BRIEF-Definium Therapeutics Announces First Patient Dosed In AscendMay 12 (Reuters) - Definium Therapeutics Inc DFTX.O:DEFINIUM THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN ASCEND, THE SECOND PHASE 3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA1J1TPL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634221890","title":"Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 Odt in Major Depressive Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2634221890","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634221890?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:00","pubTimestamp":1778583604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA1J1TPL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634218985","title":"Definium Therapeutics Inc: Topline Data From 12-Week Double-Blind Period Is Anticipated in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2634218985","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634218985?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:00","pubTimestamp":1778583604,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA1J1TPL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634510232","title":"Definium Therapeutics grants inducement stock options for 255,340 shares to new hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2634510232","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634510232?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:01","pubTimestamp":1778529679,"startTime":"0","endTime":"0","summary":"Definium Therapeutics issued inducement stock options covering 255,340 common shares to five newly hired non-executive employees, with grant dates of April 27, May 4, May 11, 2026.Exercise price set at closing share price on each grant date.Vesting scheduled over four years, with 25% vesting on first anniversary of grant date, then remaining 75% vesting in substantially equal monthly installments over next three years, subject to continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on May 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL8P0Dbr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633450206","title":"Definium Therapeutics Is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2633450206","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633450206?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:15","pubTimestamp":1778253300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DFTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 11:15 ET (15:15 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105677630","title":"Stock Track | Definium Therapeutics Plummets 5.34% Intraday Following Analyst Price Target Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=1105677630","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105677630?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:35","pubTimestamp":1778247358,"startTime":"0","endTime":"0","summary":"Definium Therapeutics' stock plummeted 5.34% during intraday trading on Friday.The decline follows Piper Sandler analyst David Amsellem lowering the firm's price target on Definium Therapeutics to...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633595534","title":"RBC Capital Reaffirms Their Buy Rating on Definium Therapeutics (DFTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633595534","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633595534?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:41","pubTimestamp":1778244066,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Definium Therapeutics, with a price target of $36.00. Th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-buy-rating-on-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-buy-rating-on-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633257458","title":"Definium Therapeutics price target lowered to $48 from $49 at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2633257458","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633257458?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:19","pubTimestamp":1778239157,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst David Amsellem lowered the firm’s price target on Definium Therapeutics (DFTX) to $48 from $49 and keeps an Overweight rating...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-price-target-lowered-to-48-from-49-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-price-target-lowered-to-48-from-49-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633175436","title":"Analysts Offer Insights on Healthcare Companies: Alcon (ALC), Argenx Se (ARGX) and Definium Therapeutics (DFTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633175436","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633175436?lang=en_us&edition=fundamental","pubTime":"2026-05-08 16:51","pubTimestamp":1778230270,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alcon (ALC), Argenx Se (ARGX) and Definium Therapeutics (DFTX). A...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alcon-alc-argenx-se-argx-and-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alcon-alc-argenx-se-argx-and-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJT1NW94.SGD","BK4198","IE00B2B36J28.USD","BK4588","IE00BFTCPJ56.SGD","HCSG","IE0009355771.USD","BK4137","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4581","LU1983260115.SGD","ARGX","LU0320765992.SGD","BK4007","LU0109394709.USD","BK4139","LU2265009873.SGD","IE0034235188.USD","XLV","LABU","XBI","BK4534","IE0002141913.USD","LU0889565916.HKD","LU0128526141.USD","LU1804176565.USD","ALC","BK4585","LU2324357040.USD","DFTX","BK4505","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633105303","title":"Definium Therapeutics releases corporate presentation outlining DT120 ODT Phase 3 program in GAD, MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2633105303","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633105303?lang=en_us&edition=fundamental","pubTime":"2026-05-08 06:46","pubTimestamp":1778193961,"startTime":"0","endTime":"0","summary":"Definium outlined late-stage plans for DT120 ODT, its lead program, with five Phase 3 studies across generalized anxiety disorder and major depressive disorder.Three Phase 3 readouts are anticipated in 2026, framed as key catalysts for potential commercial opportunities in GAD and MDD.Cash, cash equivalents, and investments totaled USD 373.4 million as of March 31, 2026, with cash runway expected to extend into 2028.Phase 2b data highlighted a single 100 g dose with a 21.9-point HAM-A improvement at Week 12, a 7.7-point placebo-adjusted difference, and 48% remission at Week 12.Pipeline also includes DT402, an R(-)-MDMA program in development for autism spectrum disorder.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeut","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDLsffrC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633177976","title":"Definium Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633177976","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633177976?lang=en_us&edition=fundamental","pubTime":"2026-05-08 05:01","pubTimestamp":1778187702,"startTime":"0","endTime":"0","summary":"Definium Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryDefinium Therapeutics Inc DFTX.OQ reported a quarterly adjusted loss of 71 cents per share for the quarter en","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL8N41K3AN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633949179","title":"Definium Therapeutics Q1 net loss widens on higher R&D costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2633949179","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633949179?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:11","pubTimestamp":1778184709,"startTime":"0","endTime":"0","summary":"Definium Therapeutics Q1 net loss widens on higher R&D costsOverviewUS biopharma firm posted wider Q1 net loss as R&D and admin expenses increasedCompany ended Q1 with $373.4 mln in cash, seen funding","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL1N41K1HT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633396179","title":"Definium Therapeutics Q1 EPS $(0.71) Misses $(0.48) Estimate. Cash And Equivalents Of $373.4M","url":"https://stock-news.laohu8.com/highlight/detail?id=2633396179","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633396179?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:09","pubTimestamp":1778184590,"startTime":"0","endTime":"0","summary":"Definium Therapeutics (NASDAQ:DFTX) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.48) by 47.92 percent. This is a 102.86 percent decrease over losses of $(0.35) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52388273/definium-therapeutics-q1-eps-0-71-misses-0-48-estimate-cash-and-equivalents-of-373-4m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Definium Therapeutics Q1 EPS $(0.71) Misses $(0.48) Estimate. Cash And Equivalents Of $373.4M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633176393","title":"Definium Q1 FY26 net loss widens to $77.1 million; R&D expense jumps 77.5% to $41.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633176393","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633176393?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:02","pubTimestamp":1778184153,"startTime":"0","endTime":"0","summary":"Definium Therapeutics posted a net loss of USD 77.1 million, widening from USD 23.3 million a year earlier; loss per share deepened to USD 0.71 from USD 0.27.Operating loss widened to USD 59.2 million from USD 32.2 million as R&D expenses climbed to USD 41.5 million from USD 23.4 million.Cash, cash equivalents, and investments fell to USD 373.4 million from USD 411.6 million at Dec. 31, 2025; cash runway expected to extend into 2028.Enrollment completed for Phase 3 Emerge in MDD and Phase 3 Voyage in GAD, with topline data expected in late 2Q 2026 and early 3Q 2026.Panorama GAD target enrollment updated to 200 with screening closed, pushing topline data to late 3Q 2026; Phase 3 PTSD study Haven planned for 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL9NBlDx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633864176","title":"BRIEF-Definium Therapeutics Inc Q1 Net Income USD -77.098 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633864176","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633864176?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:01","pubTimestamp":1778184105,"startTime":"0","endTime":"0","summary":"BRIEF-Definium Therapeutics Inc Q1 Net Income USD -77.098 Million\n\n\nMay 07 (Reuters) - Definium Therapeutics Inc Q1 operating expenses USD 59.22 million.\n\nQ1 EPS USD -0.71\nQ1 basic EPS USD -0.71\nQ1 income from operations USD -59.22 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLXB42F30:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632766536","title":"Definium Therapeutics to report first-quarter results in webcast update","url":"https://stock-news.laohu8.com/highlight/detail?id=2632766536","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632766536?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:02","pubTimestamp":1777579354,"startTime":"0","endTime":"0","summary":"Definium Therapeutics will host live webcast May 7, 2026 at 4:30 p.m. EDT to report first-quarter 2026 financial results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on April 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDLbkzGLQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631935635","title":"Definium Therapeutics Inc : Needham Raises Target Price to $38 From $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2631935635","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631935635?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:04","pubTimestamp":1777547091,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nFWN41D102:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.definiumtx.com;ir.definiumtx.com","stockEarnings":[{"period":"1week","weight":-0.0602},{"period":"1month","weight":-0.0108},{"period":"3month","weight":0.3561},{"period":"6month","weight":0.9392},{"period":"1year","weight":2.4553},{"period":"ytd","weight":0.6438}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0819},{"period":"3month","weight":0.0896},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.2649},{"period":"ytd","weight":0.0886}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.130491},{"month":2,"riseRate":0.8,"avgChangeRate":0.136845},{"month":3,"riseRate":0.4,"avgChangeRate":0.072082},{"month":4,"riseRate":0.8,"avgChangeRate":0.037703},{"month":5,"riseRate":0.5,"avgChangeRate":-0.001066},{"month":6,"riseRate":0.4,"avgChangeRate":-0.111207},{"month":7,"riseRate":0.8,"avgChangeRate":0.20763},{"month":8,"riseRate":0.2,"avgChangeRate":-0.091548},{"month":9,"riseRate":0.2,"avgChangeRate":-0.174855},{"month":10,"riseRate":0.6,"avgChangeRate":0.009639},{"month":11,"riseRate":0.4,"avgChangeRate":0.026551},{"month":12,"riseRate":0.4,"avgChangeRate":-0.08416}],"exchange":"NASDAQ","name":"Definium Therapeutics","nameEN":"Definium Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Definium Therapeutics(DFTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Definium Therapeutics(DFTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Definium Therapeutics,DFTX,Definium Therapeutics股票,Definium Therapeutics股票老虎,Definium Therapeutics股票老虎国际,Definium Therapeutics行情,Definium Therapeutics股票行情,Definium Therapeutics股价,Definium Therapeutics股市,Definium Therapeutics股票价格,Definium Therapeutics股票交易,Definium Therapeutics股票购买,Definium Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Definium Therapeutics(DFTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Definium Therapeutics(DFTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction